Post-transplantation prophylaxis and treatments for antibody-mediated rejection of solid organ transplant
US11865175B1 · kind B1 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2018 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Aug 16, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods for treating, inhibiting, reducing the likelihood of and/or reducing the severity of antibody-mediated rejection (ABMR) in a subject with organ transplantation, by selecting a subject that has undergone an organ transplant; and administering to the subject a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent to the subject after transplantation, or both before and after transplantation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.